Briumvi's superior efficacy, safety, and cost advantages are driving strong sales growth and positioning it as a best-in-class RMS therapy. Despite new competition from Roche's SC Ocrevus, Briumvi's ...
TG Therapeutics (TGTX) announced that it has completed its previously authorized $100M share repurchase program, which was initially announced in August 2024. Under that program, the Company ...
TG Therapeutics, Inc. (TGTX) on Wednesday stated that its board of directors has authorized a new share repurchase program to acquire up to an additional $100 million of the company’s common stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback